443 related articles for article (PubMed ID: 36248808)
41. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
42. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration.
Li J; Wang S; Wang N; Zheng Y; Yang B; Wang X; Zhang J; Pan B; Wang Z
Cell Commun Signal; 2021 Aug; 19(1):89. PubMed ID: 34461944
[TBL] [Abstract][Full Text] [Related]
43. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
Budhu S; Schaer DA; Li Y; Toledo-Crow R; Panageas K; Yang X; Zhong H; Houghton AN; Silverstein SC; Merghoub T; Wolchok JD
Sci Signal; 2017 Aug; 10(494):. PubMed ID: 28851824
[TBL] [Abstract][Full Text] [Related]
44. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
[TBL] [Abstract][Full Text] [Related]
45. Targeting tumor-infiltrating tregs for improved antitumor responses.
Qin D; Zhang Y; Shu P; Lei Y; Li X; Wang Y
Front Immunol; 2024; 15():1325946. PubMed ID: 38500876
[TBL] [Abstract][Full Text] [Related]
46. Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment.
Scott EN; Gocher AM; Workman CJ; Vignali DAA
Front Immunol; 2021; 12():702726. PubMed ID: 34177968
[TBL] [Abstract][Full Text] [Related]
47. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
48. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma.
Tang Y; Xu X; Guo S; Zhang C; Tang Y; Tian Y; Ni B; Lu B; Wang H
PLoS One; 2014; 9(3):e91551. PubMed ID: 24637664
[TBL] [Abstract][Full Text] [Related]
49. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
50. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.
Chew V; Lai L; Pan L; Lim CJ; Li J; Ong R; Chua C; Leong JY; Lim KH; Toh HC; Lee SY; Chan CY; Goh BKP; Chung A; Chow PKH; Albani S
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5900-E5909. PubMed ID: 28674001
[TBL] [Abstract][Full Text] [Related]
51. Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges.
Pacella I; Piconese S
Front Immunol; 2019; 10():1889. PubMed ID: 31507585
[TBL] [Abstract][Full Text] [Related]
52. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.
Granito A; Muratori L; Lalanne C; Quarneti C; Ferri S; Guidi M; Lenzi M; Muratori P
World J Gastroenterol; 2021 Jun; 27(22):2994-3009. PubMed ID: 34168403
[TBL] [Abstract][Full Text] [Related]
53. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
[TBL] [Abstract][Full Text] [Related]
54. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
[TBL] [Abstract][Full Text] [Related]
55. Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy.
Riaz F; Huang Z; Pan F
Front Immunol; 2023; 14():1280741. PubMed ID: 37936703
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer.
Fattori S; Roux H; Connen E; Robert L; Gorvel L; Le Roy A; Houacine J; Foussat A; Chretien AS; Olive D
Cancer Res; 2022 Nov; 82(21):3868-3879. PubMed ID: 36040356
[TBL] [Abstract][Full Text] [Related]
57. Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells.
Vick SC; Kolupaev OV; Perou CM; Serody JS
J Immunol; 2021 Nov; 207(10):2598-2607. PubMed ID: 34607937
[TBL] [Abstract][Full Text] [Related]
58. Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment.
Zhang S; Ke X; Zeng S; Wu M; Lou J; Wu L; Huang P; Huang L; Wang F; Pan S
Cell Mol Immunol; 2015 Sep; 12(5):580-91. PubMed ID: 26166762
[TBL] [Abstract][Full Text] [Related]
59. Role of CD4
Hariyanto AD; Permata TBM; Gondhowiardjo SA
Immunol Med; 2022 Jun; 45(2):94-107. PubMed ID: 34495808
[TBL] [Abstract][Full Text] [Related]
60. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
